PUBLISHER: Grand View Research | PRODUCT CODE: 1726308
PUBLISHER: Grand View Research | PRODUCT CODE: 1726308
The global clinical laboratory tests market size is estimated to reach USD 213.04 billion by 2030, registering a CAGR of 8.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the clinical laboratory tests market is attributable to the rising prevalence of target diseases. The use of clinical laboratory tests is on a rise owing to the use of tests in a wide variety of diagnostic purposes that primarily focus on patient health leading to evaluating and formulating proper diagnosis and treatment.
The global geriatric population is increasing and is considered as being the greatest risk factor for the development of conditions, such as cardiovascular diseases and kidney dysfunction. According to WHO, the population aged above 60 years is expected to be 1 in every 6 people by 2030, which accounts for an increase from 1 billion in 2020 to 1.4 billion by 2030. In addition, the number of people aged 80 and above is projected to double to over 1.5 billion by 2050, and people aged above 80 years are expected to triple and reach 426 Billion. Thus, the growing geriatric population is expected to be a high-impact rendering driver for this market over the forecast period.
The growing prevalence of target diseases, such as CVD and diabetes, is anticipated to boost the market over the forecast period. CVD is fatal and leading cause of death worldwide. Presence of high unmet medical needs pertaining to cardiovascular diseases and the subsequent rise in patient awareness are among factors expected to boost the demand for point-of-care lipid testing. According to WHO, in 2021, cardiovascular diseases have been leading cause of mortality and morbidity worldwide in the last three decades, 17.7 Billion people die every year due to cardiovascular diseases, which is 31% of all the deaths worldwide.
Furthermore, key players involved in developing and formulating clinical laboratory tests are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. In addition, increasing adoption of laboratory automation systems is expected to boost the market over the forecast period. For instance, in January 2023[, BD launched a third-generation total laboratory automation system, which automates lab specimen processing for microbiology laboratories. Moreover, in January 2023, NovoPath LLC expanded its LIS solutions for oncology laboratories.